Skip to main content
MDLN logo

Medline Inc. (MDLN) Stock: Price, Forecast & Analyst Target

Medline Inc. (MDLN) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $37.84 (-3.37%), as of the Nov 19, 2026 trading session; market cap $49.8B.

Educational signal · not a buy or sell recommendation · How to read this

$37.84 −$1.32 (-3.37%) Market Cap $49.8B

Medline Inc. · MDLN · NASDAQ · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-12: Medline manufactures its own medical and surgical supplies while also distributing outside brands and managing healthcare supply chains. Revenue continues to expand, but the defining test is whether stronger gross profit can reach operating and net income while overhead and debt absorb a large share of the economics.

Price as of Nov 19, 2026

Key Statistics

72 of 100

MoonshotScore v2 · Medline (MDLN)

Strong
Business Quality Solid (70)
Financial Safety Okay (49)
Valuation Fair (70)
Growth Durability Growing (77)
Momentum Rising (76)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • Altman Z 2.15 · Piotroski F 8
  • ROE 4.8% · ROA 2.7% · current ratio 4.04

Helping: business quality, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MDLN (57 recorded, newest six shown)
RecordedScoreBand
74Strong
74Strong
72Strong
72Strong
72Strong
72Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$37.84
Change on the day-3.37%
52-week range$31.37–$50.88
Market capitalisation$49.8B—
Price / earnings (trailing)56.24
Shares traded on the day10.34M
Beta (volatility vs the S&P 500)-0.39

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Dec 19, 2025 to Nov 19, 2026: low $32, high $50, latest $38. $50 $32 high $50 Dec 19, 2025 Nov 19, 2026 · $38 $42Dec 19, 2025$41Jan 2, 2026$44Jan 16, 2026$44Jan 30, 2026$45Feb 13, 2026$48Feb 27, 2026$41Mar 13, 2026$41Mar 27, 2026$46Apr 10, 2026$45Apr 24, 2026$40May 8, 2026$37May 22, 2026$34Jun 5, 2026$36Jun 18, 2026$43Jul 2, 2026$40Jul 17, 2026$39Jul 31, 2026$36Aug 14, 2026$35Aug 28, 2026$33Sep 11, 2026$35Sep 25, 2026$36Oct 9, 2026$34Oct 23, 2026$40Nov 6, 2026$38Nov 19, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Medline (MDLN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Moderate

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Weak
Gross Margin Weak

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Medline (MDLN), and what does it report?

Short answer · as of

Medline sells routine care supplies, surgical products, laboratory and diagnostic equipment, and infection-control goods to hospitals, surgical centers, physician practices, nursing homes, and other care facilities.

Demand therefore comes from recurring clinical consumption as well as procedure activity, testing, and facility supply needs.

2 · Latest results

What do the latest results show for Medline (MDLN)?

The latest period brought a revenue rebound and the highest gross profit in the presented series. Operating profit nevertheless edged lower and net income contracted sharply as selling, general, and administrative expense rose, so the improvement in product economics did not flow through to shareholders. Revenue and reported earnings exceeded estimates, while operating cash flow strengthened markedly.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Mar 2025$6.64B$322M—
Q4 FY2025$7.79B$182M$0.22 (diluted)
Q1 FY2026$7.35B$129M$0.16 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Medline (MDLN)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash has accumulated rapidly and recent operations have produced substantial cash, giving Medline ample near-term liquidity. Debt remains far above cash, however, leaving the company firmly in a net-debt position; strong liquidity ratios should not be mistaken for a lightly financed balance sheet.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 56.24 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Medline (MDLN)?

Short answer · as of

Current published price targets run low $37.00 · high $55.00 · consensus $44.20 · median $44.00 against a quoted price of $37.84 (as of Nov 19, 2026).

Watch whether revenue growth continues to lift gross profit without another disproportionate rise in overhead. The relevant confirmation is renewed operating-income growth, better conversion into net income, and operating cash flow that remains strong enough to fund investment while cash continues closing the gap with debt.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Medline compare with its peers?

Short answer

Medline's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Medline is neither merely a medical-product manufacturer nor merely a distributor. Its proprietary supplies sit beside outside-brand sourcing, logistics consulting, warehousing support, inventory rationalization, specialized packaging, and route planning, creating a broader relationship with care providers than a product-only supplier would have.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ResMed Inc. (RMD) Named competitor$242.61 Nov 18, 2026$34.1B95 5-pillar Nov 18, 2026
Intuitive Surgical, Inc. (ISRG) Same industry, near in market value$420.95 Nov 18, 2026$146B94 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.37 Nov 19, 2026$5.48B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.41 Nov 19, 2026$5.06B81 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Same industry, near in market value$74.52 Nov 19, 2026$35.8B80 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$175.76 Nov 19, 2026$4.40B73 5-pillar Nov 18, 2026
Medline (MDLN) — this page$37.84$49.8B72
Avantor, Inc. (AVTR) Named competitor$15.12 Nov 19, 2026$10.3B71 5-pillar Nov 18, 2026
Repligen Corporation (RGEN) Same industry, near in market value$170.29 Nov 19, 2026$10.9B71 5-pillar Nov 18, 2026
Becton, Dickinson and Company (BDX) Same industry, near in market value$212.73 Nov 19, 2026$57.9B68 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$163.40 Nov 19, 2026$6.48B61 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$37.00 – $55.00
Consensus target
$44.20
Median target
$44.00

Consensus record · Captured .

Measured against a quoted price of $37.84 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 8, 2026

Transactions
22
Identified insiders
5
Purchases
0
Sales
16
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MDLN in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Viking GlobalAndreas HalvorsenQ3 20260%$0Sold out (was $190.93M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Medline (MDLN)?

Read these with our analysis →

What Investors Ask About Medline (MDLN) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How do Medline Brand and Supply Chain Solutions differ?

Medline Brand manufactures or sources proprietary clinical products spanning frontline care, surgery, laboratories, and diagnostics. Supply Chain Solutions distributes outside brands and provides logistics, warehousing, inventory, packaging, and route-planning services.

Why can Medline sales rise while earnings weaken?

Recent revenue and gross profit increased, but higher selling, general, and administrative expense prevented that improvement from reaching operating profit and net income. The key mechanism is therefore expense absorption, not merely sales growth.

What matters about Medline’s Tracy and Stockton facilities?

Tracy is already occupied and management expects it to begin serving customers later in the calendar, while Stockton occupancy is planned after the calendar turns. Their importance lies in whether added distribution capacity supports service and growth without keeping overhead elevated.

Does Medline’s growing cash balance remove its debt pressure?

Cash has risen rapidly, but it remains well below total debt, leaving substantial net debt. Recent cash generation improves flexibility without eliminating the leverage burden.

What is the MDLN stock price today?

The last price recorded for Medline Inc. (MDLN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MDLN price target?

The analyst consensus price target for Medline Inc. (MDLN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Sector / industry (provider taxonomy); Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt
  • 1. What is Medline (MDLN), and what does it report?: Business description
  • 2. What do the latest results show for Medline (MDLN)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 4 quarters; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Medline (MDLN)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • 4. What should you watch next at Medline (MDLN)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Cash against market value
  • 5. How does Medline compare with its peers?: Business description; Sector / industry (provider taxonomy)
  • FAQ: How do Medline Brand and Supply Chain Solutions differ?: Business description
  • FAQ: Why can Medline sales rise while earnings weaken?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: What matters about Medline’s Tracy and Stockton facilities?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands)
  • FAQ: Does Medline’s growing cash balance remove its debt pressure?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.